EHA 2023 | Real-world outcomes of brexu-cel in patients with R/R MCL
Nausheen Ahmed
• 9 Jun 2023
Nausheen Ahmed, MD, University of Kansas Medical Center, Kansas City, MO, briefly comments on a study evaluating the real-world outcomes of patients with mantle cell lymphoma (MCL) treated with brexucabtagene autoleucel (brexu-cel). Dr Ahmed explains that the results were similar to what was observed in the ZUMA-2 trial (NCT02601313), with similar efficacy measures and no new safety signals. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kite: consulting, BMS: advisory board
